Company intelligence / Profile preview

Hengtong

Beijing, Beijing, China

Ownership: Private
Development stage: Commercial

Overview

Beijing Ketuo Hengtong Biotechnology develops and sells edible probiotics and animal/plant microecological preparations. It has built Asia's largest lactic acid bacteria strain resource bank with over 35,000 strains preserved. The company supplies clinical-grade probiotics for national sports teams and hospitals across China. Its products are supported by more than 60 clinical trials involving over 4,000 real cases.

Modalities: ProbioticMicrobial therapy
Industry: Food & Nutrition

Partnerships

Supplies preparation products for Chinese national sports teams and collaborates with top tertiary hospitals in China

Beyond the preview

Go deeper on Hengtong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hengtong.

Explore the full profile